重药控股股份有限公司独立董事 2024 年度述职报告 重药控股股份有限公司 2024 年度独立董事述职报告 刘胜强 2024 年，本人作为重药控股股份有限公司（以下简称"公司"）独立董事， 严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董事管理 办法》等法律法规、规范性文件和《公司章程》等有关要求，充分发挥自身专业 优势，诚实、勤勉、独立履行职责，推动董事会科学决策，促进公司合规治理， 依法维护公司及全体股东的合法权益。现就年度履职情况作如下报告： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人刘胜强，男，1978 年出生，中国国籍，无境外永久居留权。会计学博 士（后），教授，博士生导师，重庆会计领军人才，重庆首批会计咨询专家。现 任重庆工商大学财务与会计研究中心主任，同时担任重药控股股份有限公司、江 西世龙实业股份有限公司、三羊马（重庆）物流股份有限公司独立董事和澳斯康 生物（南通）股份有限公司董事；曾赴香港浸会大学和美国加州州立大学做访问 学者。 （二）不存在影响独立性的情况 经自查，本人确认符合《上市公司独立董事管理办法》以及《深圳证券交易 所上市公司自律监管指引第 1 号—— ...

重药控股股份有限公司 公司债券信息披露管理办法 第一章 总则 第一条 为规范重药控股股份有限公司（以下简称"重药控股"或"公司"）公司 债券信息披露行为，加强信息披露事务管理，保护公司和投资者合法权益，依据《 中华人民共和国公司法》、《中华人民共和国证券法》等国家有关法律、法规及《 公司信用类债券信息披露管理办法》（中国人民银行、中华人民共和国国家发展和 改革委员会、中国证券监督管理委员会公告〔2020〕第 22 号）、《深圳证券交易 所公司债券存续期监管业务指引第 1 号——定期报告（2023 年 10 月修订）》（深 证上〔2023〕977 号）、《公司章程》等有关规定，结合公司实际情况，制定本管 理办法。 第二条 本办法所称信息，是指可能对公司偿债能力或公司债券价格产生重 大影响的信息，以及中国证券监督管理委员会（以下简称"中国证监会"）、证券交 易所等机构要求披露的其他信息。本办法适用于重药控股发行的公司债券。 第六条 公司公开发行的公司债券，信息披露内容包括发行阶段的发行与募 集信息、存续期内的定期报告和临时报告。 第七条 公司债券发行阶段的发行与募集信息应按照中国证监会、证券交易 所等机构要求的信 ...

重药控股股份有限公司独立董事 2024 年度述职报告 重药控股股份有限公司 2024 年度独立董事述职报告 蔡仲曦 根据《公司法》《上市公司独立董事管理办法》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》等相关法律法规和规章制度的 规定，以及《公司章程》等要求，本人作为重药控股股份有限公司（以下简称"公 司"）的独立董事，现向董事会和股东会提交年度述职报告，对履行职责的情况 进行说明。 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人蔡仲曦，男，1965 年出生，中国国籍，中欧国际工商学院 EMBA，副 主任药师。现任弘盛（浙江自贸区）股权投资基金管理合伙企业（有限合伙）合 伙创始人等职务；曾任北京解放军 302 医院医师、深圳南方药厂（三九集团）经 贸部华东区经理、香港爱比斯化学公司市场部经理、国药集团上海公司副总经理、 国药控股上海公司总经理、国药控股医院营销事业部总经理、上海盛泰医疗科技 有限公司董事长，国药控股股份有限公司副总裁等职务。自 2023 年 11 月 30 日 起任公司第九届董事会独立董事。 （二）不存在影响独立性的情况 本人对独立性情况进行了自查，任职 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1600 | 0.3600 | -55.56 | 0.5500 | | 每股净资产（元） | 6.55 | 6.51 | 0.61 | 6.11 | | 每股公积金(元) | 1.44 | 1.44 | 0 | 1.4 | | 每股未分配利润(元) | 4.08 | 4.02 | 1.49 | 3.68 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 805.62 | 783.97 | 2.76 | 678.29 | | 净利润(亿元) | 2.83 | 6.25 | -54.72 | 9.52 | | 净资产收益率(%) | 2.50 | 5.99 | -58.26 | 9.30 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 111931.82万股，累计占流通股比： 64.76%，较 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥20,612,096,609.18, representing a 5.03% increase compared to ¥19,624,282,945.17 in the same period last year[4] - Net profit attributable to shareholders increased by 21.63% to ¥125,235,079.12 from ¥102,960,760.48 year-on-year[4] - The basic earnings per share rose by 16.67% to ¥0.07 from ¥0.06 in the same period last year[4] - The net profit for the current period is CNY 172,505,204.48, an increase of 28% compared to CNY 134,762,927.50 in the previous period[26] - The total profit for the current period is CNY 211,332,204.89, up from CNY 174,736,429.14, reflecting a growth of approximately 21%[26] - The operating profit increased to CNY 214,020,790.04 from CNY 173,133,845.71, representing a growth of about 23.6%[26] Cash Flow and Investments - The net cash flow from operating activities improved by 31.31%, with a net outflow of ¥2,164,537,368.43 compared to ¥3,151,359,275.90 in the previous year[13] - The cash flow from operating activities shows a net outflow of CNY -2,164,537,368.43, an improvement from CNY -3,151,359,275.90 in the previous period[27] - The cash flow from investing activities resulted in a net outflow of CNY -105,831,484.60, worsening from CNY -45,631,299.60 in the previous period[28] - The cash flow from financing activities recorded a net outflow of CNY -157,305,806.73, compared to CNY -416,716,243.92 in the previous period, indicating a reduction in outflow[28] - The company received CNY 20,324,203,721.64 in cash from sales of goods and services, slightly down from CNY 20,544,094,300.40 in the previous period[27] - The company’s total cash inflow from financing activities was CNY 5,189,064,692.62, down from CNY 5,854,431,253.78 in the previous period[28] Assets and Liabilities - The company's total assets increased by 2.81% to ¥68,503,313,875.43 from ¥66,630,329,742.10 at the end of the previous year[4] - Total liabilities rose to ¥51,829,475,163.84, compared to ¥50,166,885,104.58, an increase of 3.31%[22] - The equity attributable to shareholders increased to ¥11,443,450,307.18 from ¥11,327,166,544.56, a growth of 1.03%[23] - The company's cash and cash equivalents decreased to ¥6,974,105,705.32 from ¥9,391,508,185.09, a decline of 25.00%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 42,989[15] - The largest shareholder, Chongqing Medical Health Industry Co., Ltd., holds 38.47% of shares, totaling 664,900,806 shares, with 109,867,400 shares pledged[15] - The second largest shareholder, Chongqing Urban Construction Investment (Group) Co., Ltd., holds 16.33% of shares, totaling 282,294,397 shares[15] - The top 10 shareholders collectively hold significant stakes, with the first three shareholders accounting for over 58% of total shares[15] - The top 10 unrestricted shareholders hold a total of 1,020,000,000 shares, representing a significant portion of the company's equity[16] Changes in Control and Equity - The company is undergoing a change in actual control, with a 2% equity transfer from Chongqing Huayi Holdings to China General Technology Group[17] - The equity transfer has received necessary approvals from regulatory bodies, including the State-owned Assets Supervision and Administration Commission[18] - The company has not disclosed any related party relationships among the top shareholders[16] - The company has not reported any changes in the participation of top shareholders in margin trading or securities lending[16] - The company is in the process of completing the registration of the equity transfer, which is expected to finalize soon[19] Operational Metrics - Accounts receivable increased by 10.17% to ¥36,299,396,461.50, primarily due to increased sales revenue[10] - Prepayments surged by 63.35% to ¥2,764,378,622.27, influenced by changes in payment terms from suppliers[10] - Contract liabilities grew by 91.33% to ¥1,010,344,118.27, mainly due to advance payments received from customers[10] - Total operating costs amounted to ¥20,226,976,660.08, up from ¥19,384,577,382.40, reflecting a growth of 4.35%[25] - Inventory levels slightly decreased to ¥9,900,028,565.50 from ¥9,977,409,800.46, a reduction of 0.78%[21] - Research and development expenses were recorded at ¥106,918.22, a decrease from ¥199,371.05, indicating a reduction of 46.36%[25] - Investment income decreased by 42.51% to ¥49,857,971.07, attributed to lower returns from joint ventures[12] - The company reported a 33.45% reduction in financial expenses, amounting to ¥171,590,047.67, due to a decrease in overall financing costs[12]

Financial Performance - The company's operating revenue for 2024 was approximately ¥80.56 billion, representing a year-on-year increase of 2.76% compared to ¥78.40 billion in 2023[22]. - The net profit attributable to shareholders for 2024 was approximately ¥654.96 million, a decrease of 54.69% from ¥952.28 million in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥202.05 million, down 63.41% from ¥582.57 million in 2023[22]. - The basic earnings per share for 2024 was ¥0.16, a decrease of 55.56% from ¥0.38 in 2023[23]. - The total assets at the end of 2024 were approximately ¥66.63 billion, an increase of 4.96% from ¥63.48 billion at the end of 2023[23]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥11.33 billion, up 1.00% from ¥11.22 billion at the end of 2023[23]. - The company achieved a total operating revenue of 80.56 billion yuan, with a net profit attributable to shareholders of 283 million yuan[56]. - The pharmaceutical wholesale segment generated 76.56 billion yuan, accounting for 95.03% of total revenue, while the retail segment contributed 3.69 billion yuan, representing 4.59%[59]. - The company reported a total sales cost of ¥74,572,958,281.08, with a gross profit margin of 7.43%[78]. - The company reported a net profit attributable to shareholders of RMB 282,993,622.91 for 2024, with the parent company net profit at RMB 206,514,122.67[187]. Dividend Policy - The company plans to distribute a cash dividend of 0.3 yuan per 10 shares to all shareholders, based on a total of 1,728,184,696 shares[5]. - The proposed cash dividend is RMB 0.3 per 10 shares (including tax), totaling RMB 51,845,540.88, which represents 100% of the profit distribution[190]. - The total number of shares for the dividend distribution is 1,728,184,696, leading to an annual cumulative cash dividend of RMB 103,691,081.76 (including tax) for 2024[190]. Business Strategy and Market Position - The company has undergone significant changes in its main business focus, shifting towards pharmaceutical research and sales, health management, and hospital management since its rebranding in 2017[21]. - The company is focused on expanding its market presence in grassroots healthcare as urban medical resources are directed towards county-level hospitals and rural areas[41]. - The company is committed to upgrading its business model by integrating wholesale and retail operations, enhancing its product offerings in the health sector, and extending its pharmaceutical supply chain[110]. - The company plans to expand its market presence by implementing the "300 Cities" strategy, focusing on seamless market access and network coverage in underrepresented cities[109]. - The company has established a presence in 30 provinces and regions, covering 142 cities, through both organic growth and acquisitions in 10 new markets[56]. - The company has expanded its market presence by establishing a presence in 10 new blank markets, extending its "300 Cities" strategy to 142 prefecture-level cities[131]. Research and Development - The company invests 5% of its revenue annually in R&D, focusing on innovative drug development, with over 60% of products achieving dual registration in China and the US[75]. - The company is actively developing new products, with a focus on innovative drug formulations expected to launch in Q3 2024[149]. - The company launched several new products, including Olmesartan Medoxomil Tablets and Pregabalin Capsules, which are expected to enhance competitiveness in their respective markets[86]. - The company has completed a strategic acquisition of a smaller biotech firm for 50 million, enhancing its R&D capabilities[149]. Market Trends and Industry Insights - The pharmaceutical circulation market is expected to continue expanding, with a projected GDP growth of 5.3% in 2024, indicating strong market potential[31]. - The per capita health expenditure for residents in 2024 reached ¥2,547, a 3.6% increase from 2023, reflecting a growing emphasis on health[31]. - The retail pharmaceutical market's concentration increased, with the top 100 companies' market share growing from 35.3% in 2020 to 37.8% in 2023[33]. - The pharmaceutical industry is experiencing a shift from "scale expansion" to "quality revolution," particularly in the traditional Chinese medicine sector, with stricter quality control measures being implemented[36]. Corporate Governance and Management - The company emphasizes the responsibilities of the "key minority" and has conducted training on compliance and risk awareness for them during the reporting period[137]. - The board of directors consists of 11 members, including 4 independent directors, which meets the legal requirements[139]. - The company has established a complete financial accounting system and maintains financial independence from its controlling shareholders[141]. - The company has a diverse management team with backgrounds in finance, engineering, and pharmaceuticals, enhancing its operational capabilities[165][166]. - The company has implemented a series of revised management measures to enhance operational compliance and governance[140]. Compliance and Risk Management - The company is committed to strengthening internal controls and risk management, with a focus on digital regulatory enhancements and ensuring drug safety[117]. - The company has developed an audit early warning system with 110 warning indicators, enhancing risk management capabilities[134]. - The company maintained effective internal controls over financial reporting as of December 31, 2024, in all material respects[196]. - The internal control audit report received a standard unqualified opinion, indicating no significant deficiencies in financial reporting[196]. Employee and Labor Relations - The total number of employees at the end of the reporting period is 13,820, with 58 from the parent company and 13,762 from major subsidiaries[182]. - The company has established a tiered salary system combined with performance assessments, ensuring timely and full payment of employee salaries[184]. - The company implements an enterprise annuity system to safeguard employee interests while improving labor cost management efficiency[184]. - The company plans to conduct 38.5 million training sessions in 2024, enhancing employee growth and organizational development[185]. Environmental, Social, and Governance (ESG) - The company is committed to optimizing its ESG governance framework, aiming for a balance between environmental, social, and economic benefits[128]. - The company has published its 2024 Sustainable Development Report on the same day, detailing its social responsibility efforts[200]. - The company is not classified as a key pollutant discharge unit and has not faced administrative penalties related to environmental issues during the reporting period[199].

此刻摆在重药控股面前的，不仅是财务洗澡的阵痛，更是如何将千亿规模转化为真实价值的终极命题。 当潮水退去，唯有真正穿上"效率救生衣"的企业，才能穿越行业周期。 本文结合AI工具生成 市值管理考核下的业绩迷途 此次财务造假风波，恰逢国资委将市值管理纳入央企考核的关键节点。2023年报显示，重药控股管理层 股权激励行权条件要求净利润年复合增长率不低于10%，而实际业绩已连续三年负增长。 这种现象并非孤例。2023年白云山第四季度突然计提3亿元亏损，被指是为新任管理层卸下历史包袱； 九州通2022年也曾因提前确认收入被问询。这些案例折射出流通企业在规模扩张与质量提升间的集体迷 失——商务部数据显示，TOP5企业已占据医药流通市场52%份额，但行业平均净利率从2018年的1.8% 下滑至2023年的1.2%。 4月18日深夜，重药控股连收重庆证监局行政监管措施与深交所监管函，直指其2023年年报存在四类财 务确认违规：未实质取得货权却确认收入、无商业实质交易入账、期后大额异常退货、收入确认时点与 会计政策不符。值得关注的是，此次暴雷恰逢公司实控权由重庆国资委转至国务院国资委不足百日，业 内猜测这或是新任控股方主动"挤水 ...

Core Viewpoint - Chongqing Pharmaceutical Holdings (重药控股) faces regulatory scrutiny due to inaccuracies in its 2023 financial reporting, leading to a decline in stock price and concerns over potential earnings manipulation [2][3]. Financial Performance - In 2023, Chongqing Pharmaceutical Holdings reported revenue of approximately 801.2 billion yuan, an increase of 18.12% year-on-year, while net profit decreased by 31.22% to about 6.55 billion yuan [3]. - The company's cash flow from operating activities showed a significant increase of 77.92%, reaching approximately 5.09 billion yuan [3]. - The company anticipates a decline in net profit for 2024, projected between 290 million and 390 million yuan, representing a year-on-year decrease of 40.45% to 55.72% [3]. Business Operations - The company primarily engages in pharmaceutical commerce, logistics, and industrial research, with a core focus on pure sales business, supplying pharmaceuticals and medical devices directly to hospitals and medical institutions [2]. - Chongqing Pharmaceutical Holdings has over 7,800 secondary and above pure sales customers, with pure sales accounting for approximately 79.37% of total sales, amounting to 635.94 billion yuan [3]. Regulatory Actions - The Chongqing Securities Regulatory Bureau issued an administrative regulatory measure against the company, citing issues such as improper revenue recognition and lack of commercial substance in certain transactions [2]. - The company's chairman, general manager, and financial director have been subjected to regulatory discussions as part of the measures taken [2]. Ownership Changes - In January 2023, the actual controller of Chongqing Pharmaceutical Holdings changed from the Chongqing State-owned Assets Supervision and Administration Commission to the State-owned Assets Supervision and Administration Commission of the State Council [4]. - The change in control was due to the transfer of 2% equity from Chongqing Chemical Medicine to China General Technology Group [5].

重药控股收到深交所监管函，公司存在以下问题：2023年，部分收入未实质取得货物控制权，错误适用 总额法进行确认；部分收入在期后大额退货，且无有效证明材料、无合理退货理由；部分收入无商业实 质；部分收入实际确认时点与公司已披露会计政策不符，上述问题导致公司2023年年度报告财务信息披 露不准确。公司的上述行为违反了相关规定。公司董事长袁泉、总经理刘伟、财务总监兼董秘邱天未履 行勤勉尽责义务，违反了相关规定，对上述问题负有主要责任。 ...

重药控股股份有限公司 关于收到重庆证监局行政监管措施决定书的公告 证券代码：000950 证券简称：重药控股 公告编号：2025-024 一、行政监管措施决定书的主要内容 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重药控股股份有限公司（以下简称"公司"）及相关人员于近日收到中国 证券监督管理委员会重庆监管局（以下简称"重庆证监局"）下发的行政监管措 施决定书，现将相关内容公告如下： 内向有管辖权的人民法院提起诉讼。复议与诉讼期间，上述监督管理措施不停 止执行。" （二）中国证券监督管理委员会重庆监管局《关于对重药控股股份有限公 司袁泉、刘伟、邱天采取监管谈话措施的决定》（〔2025〕27 号） "袁泉、刘伟、邱天： （一）中国证券监督管理委员会重庆监管局《关于对重药控股股份有限公 司采取责令改正并出具警示函措施的决定》（〔2025〕26 号） "重药控股股份有限公司： 经查，我局发现重药控股股份有限公司(以下简称重药控股或公司)存在以 下问题： 经查，我局发现你公司存在以下问题： 2023 年，你公司部分收入未实质取得货物控制权，错误适用总额法进行确 认 ...